Literature DB >> 25156513

Venous thromboembolism after major urologic oncology surgery: a focus on the incidence and timing of thromboembolic events after 27,455 operations.

Blake D Alberts1, Solomon L Woldu2, Aaron C Weinberg2, Matthew R Danzig2, Ruslan Korets2, Ketan K Badani2.   

Abstract

OBJECTIVE: To investigate the incidence and timing of venous thromboembolism (VTE) and identify risk factors for venous thromboembolism among patients undergoing major surgery for urologic malignancies. VTE events are stratified by occurrence in the inpatient vs outpatient settings.
MATERIALS AND METHODS: The National Surgical Quality Improvement Program database was queried using Current Procedural Terminology and International Statistical Classification of Diseases, Ninth Revision codes to identify patients undergoing major surgery for urologic malignancies between 2005 and 2012. The incidence of overall 30-day VTE, postdischarge VTE, and post-VTE death was calculated for each surgical procedure. Logistic regression analysis was used to identify risk factors for VTE, adjusting for covariates including age, race, gender, smoking status, medical comorbidities, performance of pelvic lymph node dissection, and operative time.
RESULTS: The study identified 27,455 patients who underwent an operation for malignancy--radical nephrectomy, partial nephrectomy, nephroureterectomy, radical prostatectomy, or radical cystectomy. The incidence and timing of VTE varied substantially across the procedures of interest. Overall, VTE occurred after radical cystectomy in 113 of 2065 of patients (5.5%), whereas only 19 of 2624 (0.7%) and 12 of 1690, respectively, of patients undergoing minimally invasive radical or partial nephrectomy procedures suffered a VTE event within 30-days of surgery. Among patients suffering a VTE after radical prostatectomy, 147 of 178 of venous thromboembolic events (82.6%) occurred after hospital discharge.
CONCLUSION: This study demonstrates the significant burden of VTE beyond the time of hospital discharge. Identification of high-risk patients should prompt consideration of extended-duration VTE prophylaxis in the outpatient setting.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25156513     DOI: 10.1016/j.urology.2014.05.055

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  18 in total

Review 1.  Venous thromboprophylaxis in urological cancer surgery.

Authors:  Wojciech Michalski; Grazyna Poniatowska; Joanna Jonska-Gmyrek; Jakub Kucharz; Pawel Stelmasiak; Karol Nietupski; Katarzyna Ossolinska-Skurczynska; Michal Sobieszczuk; Tomasz Demkow; Pawel Wiechno
Journal:  Med Oncol       Date:  2019-11-25       Impact factor: 3.064

Review 2.  Enhanced recovery protocols (ERP) in robotic cystectomy surgery. Review of current status and trends.

Authors:  Christofer Adding; Justin W Collins; Oscar Laurin; Abolfazl Hosseini; N Peter Wiklund
Journal:  Curr Urol Rep       Date:  2015-05       Impact factor: 3.092

3.  Surgery: Venous thromboembolism and urological surgery.

Authors:  Robert Phillips
Journal:  Nat Rev Urol       Date:  2014-09-09       Impact factor: 14.432

4.  Validating the role of ABO blood type in risk of perioperative venous thromboembolism after radical cystectomy.

Authors:  Sumeet Bhanvadia; Kayvan Kazerouni; Soroush T Bazargani; Gus Miranda; Jie Cai; Siamak Daneshmand; Hooman Djaladat
Journal:  World J Urol       Date:  2018-06-06       Impact factor: 4.226

5.  Validation of a frailty index in patients undergoing curative surgery for urologic malignancy and comparison with other risk stratification tools.

Authors:  Danny Lascano; Jamie S Pak; Max Kates; Julia B Finkelstein; Mark Silva; Elizabeth Hagen; Arindam RoyChoudhury; Trinity J Bivalacqua; G Joel DeCastro; Mitchell C Benson; James M McKiernan
Journal:  Urol Oncol       Date:  2015-07-09       Impact factor: 3.498

6.  A retrospective cohort study of disease-related risk factors for central venous catheter-related symptomatic thrombosis in intensive care unit inpatients.

Authors:  Zhiming Kuang; Xiaochun Liu; Yunlin Zhu; Hailiang Xie; Yuanfei Liu
Journal:  Medicine (Baltimore)       Date:  2021-07-23       Impact factor: 1.817

7.  The limited utility of currently available venous thromboembolism risk assessment tools in gynecological oncology patients.

Authors:  Emma L Barber; Daniel L Clarke-Pearson
Journal:  Am J Obstet Gynecol       Date:  2016-04-27       Impact factor: 8.661

8.  Use of venous-thrombotic-embolic prophylaxis in patients undergoing surgery for renal tumors: a questionnaire survey in the Nordic countries (The NORENCA-2 study).

Authors:  Lars Lund; Harry Nisen; Petrus Järvinen; Magnus Fovaeus; Eirikur Gudmundsson; Bjarne Kromann-Andersen; Börje Ljungberg; Frode Nilsen; Pernilla Sundqvist; Peter E Clark; Christian Beisland
Journal:  Res Rep Urol       Date:  2018-10-25

9.  Venous Thromboembolism and Peri-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-based Study.

Authors:  Kelly Brennan; Safiya Karim; R Christopher Doiron; D Robert Siemens; Christopher M Booth
Journal:  Bladder Cancer       Date:  2018-10-29

10.  Incidence and risk factors of venous thromboembolism after percutaneous nephrolithotomy: a single-center experience.

Authors:  Huimin Zeng; Meng Gao; Jinbo Chen; Yu Cui; Fang Huang; Feng Zeng; Zhongqing Yang; Yang Li; Zhiyong Chen; Zewu Zhu; Hequn Chen
Journal:  World J Urol       Date:  2021-03-16       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.